Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel Pharmacogenomics Project
NCT01097343Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clopidogrel in coronary artery disease (CAD) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU) Value >230 at 90 days. Started Mar 2010; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01097343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097343.